デフォルト表紙
市場調査レポート
商品コード
1676222

フィブリノゲン濃縮物の世界市場調査レポート:産業分析、規模、シェア、成長、動向、2025年から2033年までの予測

Global Fibrinogen Concentrates Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033


出版日
ページ情報
英文 210 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
フィブリノゲン濃縮物の世界市場調査レポート:産業分析、規模、シェア、成長、動向、2025年から2033年までの予測
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 210 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

フィブリノゲン濃縮物の世界市場規模は、2024年の41億米ドルから2033年には74億米ドルに成長し、2026~2033年の予測期間中に6.79%の堅調な年間平均成長率(CAGR)を示すと予測されています。

フィブリノゲン濃縮製剤市場は、出血性疾患の有病率の増加や、外科手術や外傷の現場における効果的な止血剤に対する需要の高まりに牽引され、大きな成長が見込まれています。凝固カスケードにおける重要なタンパク質であるフィブリノゲンは、創傷治癒と血栓形成において重要な役割を果たしています。医療プロバイダーが患者の転帰を改善し、出血に伴う合併症のリスクを低減しようと努める中、フィブリノゲン濃縮製剤の使用はますます重要になってきています。この市場には、特に大手術を受ける患者や先天性フィブリノゲン欠乏症の患者の止血を強化するために設計された様々な製品が含まれています。

技術の進歩はフィブリノゲン濃縮物市場を大きく形成しており、製造プロセスや精製技術の革新は製品の安全性と有効性を高めています。先進的分画法と病原体不活性化技術の開発により、フィブリノゲン濃縮製剤の品質が向上し、厳しい規制基準に適合するようになっています。さらに、ポイントオブケア検査とモニタリングシステムの統合により、医療プロバイダーはフィブリノゲン濃度をリアルタイムで評価できるようになり、タイムリーな介入と個別化された治療アプローチが容易になっています。市場が進化を続ける中、技術革新を優先し、研究開発に投資する企業が競合を獲得する可能性が高いです。

さらに、フィブリノゲン濃縮物市場は、さまざまな医療用途でのフィブリノゲンの使用を促進する規制の枠組みや臨床ガイドラインの影響をますます受けています。医療システムがエビデンスによる診療を採用するにつれて、厳格な臨床検査を通じて安全性と有効性を実証したフィブリノゲン濃縮製剤に対する需要は引き続き高まると考えられます。この動向は、新規用途の探索と既存製剤の改良を目的とした研究イニシアチブへの投資を促進しています。個別化医療と標的療法への注目が高まるにつれ、個々の患者のニーズに合わせたフィブリノゲン濃縮製剤へのニーズは拡大し、臨床要件に合致した製剤を提供する企業はこの重要な市場で成功を収めることができます。

当レポートは、様々な産業や市場に関する包括的かつ実用的な洞察を顧客に提供できるよう、綿密に作成されています。各レポートには、市場情勢を完全に理解するためのいくつかの重要な要素が含まれています。

市場概要:市場概要:定義、分類、産業の現状を含む市場の詳細なイントロダクション。

市場促進要因:市場成長に影響を与える主要促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析:製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢:市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場参入企業の包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を記載しています。

市場予測:過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析:地域による市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネス機会を理解するのに役立ちます。

新たな動向と機会:現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象セグメントを特定します。将来の市場開拓と成長展望に関する洞察を記載しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 フィブリノゲン濃縮物産業分析

  • イントロダクション:市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 産業動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原料分析
    • 原料リスト
    • 原料メーカー一覧
    • 主要原料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 フィブリノゲン濃縮物の世界市場分析:製品タイプ別

  • 製品タイプ別概要
  • 製品タイプ別過去・予測データ分析
  • ヒトフィブリノゲン濃縮物
  • 遺伝子組換えフィブリノゲン濃縮物
  • 動物由来フィブリノゲン濃縮物
  • 合成フィブリノゲン濃縮物

第6章 フィブリノゲン濃縮物の世界市場分析:用途別

  • 用途別概要
  • 用途別過去・予測データ分析
  • 先天性フィブリノゲン欠乏症
  • 外科的処置
  • その他

第7章 フィブリノゲン濃縮物の世界市場分析:エンドユーザー別

  • エンドユーザー別概要
  • エンドユーザー別過去・予測データ分析
  • 病院
  • 外来手術センター
  • その他

第8章 フィブリノゲン濃縮物の世界市場分析:地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米:セグメント別
    • 北米:国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州:セグメント別
    • 欧州:国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋:セグメント別
    • アジア太平洋:国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ:セグメント別
    • ラテンアメリカ:国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ:セグメント別
    • 中東・アフリカ:国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 フィブリノゲン濃縮物企業の競合情勢

  • フィブリノゲン濃縮物の市場競争
  • 提携/協力/合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Baxter International Inc
  • Shanghai RAAS
  • Octapharma AG
  • Johnson And Johnson
  • ThermoFisher Scientific
  • ProFibrix BV.
  • Enzo Life Sciences Inc
  • CSL Behring
  • GC Biopharma
  • Hualan Biological Engineering Inc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Product Type (USD MN)
  • Human Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Recombinant Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Animal-Derived Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Synthetic Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Congenital Fibrinogen Deficiency Market Sales By Geography (USD MN)
  • Surgical Procedures Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Fibrinogen Concentrates Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Fibrinogen Concentrates Report
  • Market Research Process
  • Market Research Methodology
  • Global Fibrinogen Concentrates Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Product Type
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By End User
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Product Type (USD MN)
  • Human Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Recombinant Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Animal-Derived Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Synthetic Fibrinogen Concentrate Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Congenital Fibrinogen Deficiency Market Sales By Geography (USD MN)
  • Surgical Procedures Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11216851

Global Fibrinogen Concentrates Market size is anticipated to grow from USD 4.1 Billion in 2024 to USD 7.4 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 6.79% during the forecast period of 2026 to 2033.

The Fibrinogen Concentrates market is poised for significant growth, driven by the increasing prevalence of bleeding disorders and the rising demand for effective hemostatic agents in surgical and trauma settings. Fibrinogen, a critical protein in the coagulation cascade, plays a vital role in wound healing and blood clot formation. As healthcare providers seek to improve patient outcomes and reduce the risk of complications associated with bleeding, the use of fibrinogen concentrates is becoming increasingly important. This market encompasses a range of products designed to enhance hemostasis, particularly in patients undergoing major surgeries or those with congenital fibrinogen deficiencies.

Technological advancements are significantly shaping the Fibrinogen Concentrates market, with innovations in manufacturing processes and purification techniques enhancing product safety and efficacy. The development of advanced fractionation methods and pathogen inactivation technologies is improving the quality of fibrinogen concentrates, ensuring that they meet stringent regulatory standards. Additionally, the integration of point-of-care testing and monitoring systems is enabling healthcare providers to assess fibrinogen levels in real-time, facilitating timely interventions and personalized treatment approaches. As the market continues to evolve, companies that prioritize innovation and invest in research and development will likely gain a competitive edge.

Moreover, the Fibrinogen Concentrates market is increasingly influenced by regulatory frameworks and clinical guidelines that promote the use of fibrinogen in various medical applications. As healthcare systems adopt evidence-based practices, the demand for fibrinogen concentrates that demonstrate safety and efficacy through rigorous clinical trials will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel applications and improving existing formulations. As the focus on personalized medicine and targeted therapies grows, the need for fibrinogen concentrates that can be tailored to individual patient needs will expand, positioning companies that align their offerings with clinical requirements for success in this vital market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Product Type

  • Human Fibrinogen Concentrate
  • Recombinant Fibrinogen Concentrate
  • Animal-Derived Fibrinogen Concentrate
  • Synthetic Fibrinogen Concentrate

By Application

  • Congenital Fibrinogen Deficiency
  • Surgical Procedures
  • Others

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others
  • COMPANIES PROFILED
  • Baxter International Inc
  • Shanghai RAAS
  • Octapharma AG
  • Johnson and Johnson
  • ThermoFisher Scientific
  • ProFibrix BV.
  • Enzo Life Sciences Inc
  • CSL Behring
  • GC Biopharma
  • Hualan Biological Engineering Inc.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. FIBRINOGEN CONCENTRATES INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By End User
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY PRODUCT TYPE

  • 5.1. Overview By Product Type
  • 5.2. Historical and Forecast Data Analysis By Product Type
  • 5.3. Human Fibrinogen Concentrate Historic and Forecast Sales By Regions
  • 5.4. Recombinant Fibrinogen Concentrate Historic and Forecast Sales By Regions
  • 5.5. Animal-Derived Fibrinogen Concentrate Historic and Forecast Sales By Regions
  • 5.6. Synthetic Fibrinogen Concentrate Historic and Forecast Sales By Regions

6. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY APPLICATION

  • 6.1. Overview By Application
  • 6.2. Historical and Forecast Data Analysis By Application
  • 6.3. Congenital Fibrinogen Deficiency Historic and Forecast Sales By Regions
  • 6.4. Surgical Procedures Historic and Forecast Sales By Regions
  • 6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY END USER

  • 7.1. Overview By End User
  • 7.2. Historical and Forecast Data Analysis By End User
  • 7.3. Hospitals Historic and Forecast Sales By Regions
  • 7.4. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE FIBRINOGEN CONCENTRATES COMPANIES

  • 9.1. Fibrinogen Concentrates Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF FIBRINOGEN CONCENTRATES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Baxter International Inc
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Shanghai RAAS
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Octapharma AG
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Johnson And Johnson
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. ThermoFisher Scientific
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. ProFibrix BV.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Enzo Life Sciences Inc
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. CSL Behring
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. GC Biopharma
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Hualan Biological Engineering Inc
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies